VisCardia is pioneering a truly novel Heart Failure device therapy to augment cardiac function by stimulating the diaphragm in synchrony with the cardiac cycle and thereby using it as an ancillary cardiac pump to improve blood circulation. The therapy addresses a significant gap in treatment options for patients who remain symptomatic despite being on optimized Guideline Directed Medical Treatment.
Leadership
Peter Bauer, Ph.D.
President & CEO
Peter is the President and CEO of VisCardia. He most recently served as President of Inovise Medical, after leading as its EVP of R&D. He previously held various leadership positions at BIOTRONIK focused on research and technology in their cardiac rhythm management division.
Michael Mirro, M.D.
Medical Affairs
Mike has pioneered implantable medical device development as a renowned physician investigator for over 35 years. He is board certified in internal medicine, cardiovascular disease, cardiac electrophysiology, and geriatrics, and has served as a principal investigator for over 100 clinical trials, and as a clinical advisor for multiple medical technology companies.
Alan Andresen
VP Development, RA/QA
Alan has over 30 years of experience in the development, QA/RA, regulatory and commercialization of medical devices. He previously worked for HP Medical as Senior Software Engineer and Architect
Patti Arand
VP Clinical Affairs
Patti has over 30 years of experience in research, algorithm development, clinical studies of diagnostic and therapeutic medical devices. She was previously R&D Project Manager and Engineer at HP Medical
Clinical Advisors
Lee Goldberg, MD
Professor of Medicine and Section Chief of Advanced Heart Failure and Cardiac Transplant at the University of Pennsylvania and Vice Chair of Medicine for Informatics. Published >90 articles/chapters and lectured worldwide on heart failure, cardiac transplant, mechanical circulatory support, medical informatics/data analytics, sleep apnea and palliative care.
Marat Fudim, MD
Assistant Professor of Medicine and co-director of the Heart Failure Research Unit at Duke University. Dr. Fudim is also a member of the research committee for the Heart Failure Society of America.
John Cleland, MD
Professor of Cardiology at Imperial College London and Director of the Robertson Centre for Biostatistics in Glasgow. Former chairman of the British Society for Heart Failure and of the Working Group on Heart Failure of the ESC, founder of the European Journal of Heart Failure, and influencial scholar.
Stefan Anker, MD
Professor of Homeostasis in Cardiology & Metabolism at Charité – Universitätsmedizin Berlin, specializing in heart failure and cachexia. Former President of the ESC Heart Failure Association and a highly cited researcher and leader of international clinical trials.